Drug Trial Radar · NCT05183347
A Study in Healthy Japanese Men to Test How Well Different Doses of BI 1291583 Are Tolerated
Last checked: Nov 19, 2026Latest source record: Aug 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Feb 4, 2022
Primary completion
Jul 27, 2022
Study completion Jul 27, 2022
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Jan 10, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 20 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 1291583 in healthy male Japanese subjects following oral administration of single rising doses and multiple doses.
Conditions
- Healthy
Interventions
BI 1291583Drug
BI 1291583
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of any treatment-emergent adverse event assessed as drug-related by the investigatorTime frame: up to 65 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
SOUSEIKAI Sumida Hospital
Tokyo, Sumida-ku, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.